We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?
Read MoreHide Full Article
Co-Diagnostics, Inc. (CODX - Free Report) is expected to release third-quarter 2020 results in the early weeks of November.
In the last reported quarter, the company delivered a negative earnings surprise of 29.5%. Further, it missed estimates in each of the trailing four quarters, the average negative surprise being 26.1%.
Q3 Estimates
For the third quarter, the Zacks Consensus Estimate for revenues is pegged at $28 million, suggesting significant growth from the prior-year quarter. The same for earnings per share stands at 54 cents.
Factors to Note
Co-Diagnostics has been increasing production capacity to cater to rising demand for its COVID-19 tests. Hence, the company’s third-quarter revenues are likely to reflect increase in COVID-19 test sales. This, in turn, is likely to have benefited the company’s performance in the to-be-reported quarter.
Further, sales of Logix Smart COVID-19 test kits might have contributed to expansion in gross margin.
On Sep 8, 2020, Co-Diagnostics inked a deal with Arches Research, Inc. in order to expand the latter’s COVID-19 testing services by utilizing the former’s Logix Smart COVID-19 test kit. The deal is likely to offer more opportunities for sales of additional molecular diagnostic products in Co-Diagnostics’ development pipeline.
On Aug 3, 2020, the company’s partner, Clinical Reference Laboratory (CRL), obtained FDA Emergency Use Authorization (EUA) for CRL Rapid Response, which is a saliva-based COVID-19 test. The test can easily be self-administered at home, work or any other setting and then tested using Co-Diagnostics’ patented CoPrimer technology. On Feb 24, 2020, Co-Diagnostics became the first company in the United States to receive CE marking for COVID-19 test kit.
Moreover, on Apr 6, 2020, the company received FDA EUA for its Logix Smart COVID-19 test.
The company has also received COVID-19 test orders from public and private organizations in about 50 countries and over 25 states in the United States.
These positive developments are likely to get reflected in the company’s third-quarter results.
However, the company may have experienced a rise in operating expenses, which in turn might have weighed on the to-be-reported quarter’s performance.
What Our Quantitative Model Suggests
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see.
Earnings ESP: Co-Diagnostics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Co-Diagnostics carries a Zacks Rank #4 (Sell).
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?
Co-Diagnostics, Inc. (CODX - Free Report) is expected to release third-quarter 2020 results in the early weeks of November.
In the last reported quarter, the company delivered a negative earnings surprise of 29.5%. Further, it missed estimates in each of the trailing four quarters, the average negative surprise being 26.1%.
Q3 Estimates
For the third quarter, the Zacks Consensus Estimate for revenues is pegged at $28 million, suggesting significant growth from the prior-year quarter. The same for earnings per share stands at 54 cents.
Factors to Note
Co-Diagnostics has been increasing production capacity to cater to rising demand for its COVID-19 tests. Hence, the company’s third-quarter revenues are likely to reflect increase in COVID-19 test sales. This, in turn, is likely to have benefited the company’s performance in the to-be-reported quarter.
Further, sales of Logix Smart COVID-19 test kits might have contributed to expansion in gross margin.
CoDiagnostics, Inc. Price and EPS Surprise
CoDiagnostics, Inc. price-eps-surprise | CoDiagnostics, Inc. Quote
On Sep 8, 2020, Co-Diagnostics inked a deal with Arches Research, Inc. in order to expand the latter’s COVID-19 testing services by utilizing the former’s Logix Smart COVID-19 test kit. The deal is likely to offer more opportunities for sales of additional molecular diagnostic products in Co-Diagnostics’ development pipeline.
On Aug 3, 2020, the company’s partner, Clinical Reference Laboratory (CRL), obtained FDA Emergency Use Authorization (EUA) for CRL Rapid Response, which is a saliva-based COVID-19 test. The test can easily be self-administered at home, work or any other setting and then tested using Co-Diagnostics’ patented CoPrimer technology.
On Feb 24, 2020, Co-Diagnostics became the first company in the United States to receive CE marking for COVID-19 test kit.
Moreover, on Apr 6, 2020, the company received FDA EUA for its Logix Smart COVID-19 test.
The company has also received COVID-19 test orders from public and private organizations in about 50 countries and over 25 states in the United States.
These positive developments are likely to get reflected in the company’s third-quarter results.
However, the company may have experienced a rise in operating expenses, which in turn might have weighed on the to-be-reported quarter’s performance.
What Our Quantitative Model Suggests
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see.
Earnings ESP: Co-Diagnostics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Co-Diagnostics carries a Zacks Rank #4 (Sell).
Peer Releases
Some better-ranked stocks in the broader medical space that have already announced their quarterly results are Thermo Fisher Scientific Inc. (TMO - Free Report) , Align Technology, Inc. (ALGN - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>